Amneal Pharmaceuticals (NASDAQ:AMRX) EVP Sells $1,571,723.52 in Stock

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) EVP Nikita Shah sold 131,856 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $11.92, for a total transaction of $1,571,723.52. Following the transaction, the executive vice president owned 146,403 shares in the company, valued at approximately $1,745,123.76. This trade represents a 47.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Nikita Shah also recently made the following trade(s):

• On Monday, August 25th, Nikita Shah sold 6,340 shares of Amneal Pharmaceuticals stock. The shares were sold at an average price of $9.50, for a total value of $60,230.00.
• On Friday, August 22nd, Nikita Shah sold 114,492 shares of Amneal Pharmaceuticals stock. The stock was sold at an average price of $9.66, for a total transaction of $1,105,992.72.

Amneal Pharmaceuticals Stock Up 1.0%

Shares of AMRX opened at $11.64 on Monday. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $12.12. The company has a market capitalization of $3.66 billion, a PE ratio of 1,165.17 and a beta of 1.21. The company has a 50-day simple moving average of $10.37 and a 200-day simple moving average of $8.95.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $784.51 million during the quarter. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.750-0.80 EPS. On average, research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AMRX. Vanguard Group Inc. boosted its position in shares of Amneal Pharmaceuticals by 2.3% in the third quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock worth $179,729,000 after buying an additional 403,582 shares during the period. Rubric Capital Management LP lifted its position in Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after acquiring an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Amneal Pharmaceuticals by 2.5% during the third quarter. Dimensional Fund Advisors LP now owns 5,431,134 shares of the company’s stock worth $54,361,000 after purchasing an additional 133,764 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after purchasing an additional 558,877 shares during the period. Finally, BlackBarn Capital Partners LP boosted its position in Amneal Pharmaceuticals by 19.6% in the 2nd quarter. BlackBarn Capital Partners LP now owns 3,446,570 shares of the company’s stock valued at $27,883,000 after buying an additional 564,916 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on shares of Amneal Pharmaceuticals from $12.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Piper Sandler reissued an “overweight” rating and issued a $13.00 price target (up from $11.00) on shares of Amneal Pharmaceuticals in a research note on Friday, October 31st. Four investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Amneal Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $12.50.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.